Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
6
×
detroit top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
roche
6
×
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
indiana blog main
indiana top stories
cancer
deals
investing
pfizer
startups
vertex pharmaceuticals
alzheimer's disease
amgen
biogen
cancer immunotherapy
clinical trials
cystic fibrosis
What
bio
6
×
roundup
crispr
drug
ceo
patients
plan
acquisitions
advantages
ahead
albert
alliance
alzheimer’s
asco
bar
big
biggest
bosley's
bosley’s
bourla
branded
bridge
brings
bristol
bucks
buy
calls
cas
changing
choices
color
commissioner
companies
company
consumers
costly
counterweight
crime
days
departure
Language
unset
unknown
Current search:
roche
×
bio
×
" detroit blog main "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More